TFS Capital’s Dicerna Pharmaceuticals DRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DRNA
6CM
TFS Capital's DRNA Position: Q3 2017 in Review
TFS Capital sold out of Dicerna Pharmaceuticals (DRNA) in Q3 2017, closing a stake of 14,518 shares — an estimated $46K sold.
TFS Capital first reported a position in DRNA in Q2 2014 and held it in 7 quarters. The position peaked at $1.06M in Q2 2015. 37 funds tracked by Wall St. Rank hold DRNA as of Q3 2017.
- TFS Capital reported no remaining Dicerna Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
- TFS Capital sold 14,518 Dicerna Pharmaceuticals shares in Q3 2017, an estimated $46K.
- TFS Capital first reported a position in Dicerna Pharmaceuticals in Q2 2014 and held it in 7 quarters.
- TFS Capital's Dicerna Pharmaceuticals position peaked at $1.06M in Q2 2015.
- 37 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals as of Q3 2017.
Based on TFS Capital's 13F filing for Q3 2017.